Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 beta variant RBD mRNA vaccine
- Development stage
- Phase 1
- Lead developer
- The University of Sydney
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The SARS-CoV-2 beta variant RBD mRNA vaccine is an mRNA-based vaccine designed to combat COVID-19, specifically targeting the Beta variant of SARS-CoV-2. It consists of messenger RNA (mRNA) that encodes the Receptor Binding Domain (RBD) of the Beta variant's spike protein, encapsulated within lipid nanoparticles (LNPs) for delivery. Upon intramuscular administration, host cells translate the mRNA to produce the Beta variant RBD protein. This protein then acts as an antigen, stimulating the immune system to generate both humoral (antibody) and cellular (T-cell) responses. The vaccine aims to induce neutralizing antibodies and T-cells that can recognize and neutralize the SARS-CoV-2 Beta variant, and potentially other emerging variants, thereby providing protection against infection and disease. It is also designed to overcome immune imprinting caused by prior exposure to ancestral SARS-CoV-2 strains or vaccines. The vaccine has been evaluated in Phase 1 clinical trials as a booster dose.
- Other names
- Beta RBD-TM mRNA vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on SARS-CoV-2 beta variant RBD mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 beta variant RBD mRNA vaccine.